Cover Image
市場調查報告書

麻醉效果:開發中產品分析

Anesthetic Effect - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 253649
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
麻醉效果:開發中產品分析 Anesthetic Effect - Pipeline Review, H1 2018
出版日期: 2018年03月13日 內容資訊: 英文 82 Pages
簡介

麻醉是可讓病人失去意識的醫療步驟,提升其併發症風險的要因有抽煙和閉塞型睡眠呼吸中止症,肥胖,高血壓,麻醉的副作用的病歷,對醫藥品的過敏體質等。

本報告提供全球各國的麻醉效果治療用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

麻醉效果概要

治療藥的開發

  • 開發中產品的概要
  • 企業開發中的治療藥
  • 大學/機關研究中的治療藥
  • 企業開發中的產品
  • 大學/機關研究中的產品

麻醉效果:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

麻醉效果的治療藥開發企業

  • 4P Therapeutics LLC
  • Biolab Farmaceutica Ltda
  • Drawbridge Pharmaceuticals Pty Ltd
  • Expanesthetics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Lee's Pharmaceutical Holdings Ltd
  • Lipicard Technologies Ltd
  • NanoMedex Pharmaceuticals Inc
  • Paion AG
  • Phosphagenics Ltd
  • Physica Pharma
  • Primex Pharmaceuticals Oy
  • Proteus SA
  • Sphaera Pharma Pvt Ltd
  • Taiwan Liposome Company Ltd
  • The Medicines Company
  • WEX Pharmaceuticals Inc

藥物簡介

麻醉效果:暫停中的計劃

麻醉效果:開發中止的產品

麻醉效果:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10233IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H1 2018, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 4, 2, 2, 2, 14 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anesthetic Effect - Overview
    • Anesthetic Effect - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Anesthetic Effect - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Anesthetic Effect - Companies Involved in Therapeutics Development
    • 4P Therapeutics LLC
    • Biolab Farmaceutica Ltda
    • Crescita Therapeutics Inc
    • Drawbridge Pharmaceuticals Pty Ltd
    • Expanesthetics Inc
    • Jiangsu Hengrui Medicine Co Ltd
    • Lannett Company Inc
    • Lee's Pharmaceutical Holdings Ltd
    • Paion AG
    • Phosphagenics Ltd
    • Physica Pharma
    • Primex Pharmaceuticals Oy
    • Recro Pharma Inc
    • The Medicines Company
  • Anesthetic Effect - Drug Profiles
    • alphaxalone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aom-0765 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Carboetomidate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cysteine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXPS-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXPS-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXPS-09 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Flexicaine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSK-3486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine + prilocaine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Methoxycarbonyl Carboetomidate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Methoxycarbonyl Etomidate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • midazolam hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHY-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remimazolam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remimazolam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Anesthetic Effect - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPR-819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anesthetic Effect - Dormant Projects
  • Anesthetic Effect - Discontinued Products
  • Anesthetic Effect - Product Development Milestones
    • Featured News & Press Releases
      • Dec 01, 2017: Lannett Announces FDA Acceptance Of 505(b)(2) New Drug Application For Cocaine Hydrochloride Topical Solution, A Proprietary Anesthetic Product
      • Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Koera
      • Nov 09, 2017: Phosphagenics Provides Update on TPM/Propofol Development Program
      • Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU
      • Sep 25, 2017: Lannett's Board Of Directors Initiates CEO Search
      • Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial
      • Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia
      • Oct 27, 2016: Lannett Announces Successful Phase III Clinical Trial Results For Proprietary C-Topical Product
      • Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
      • Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
      • Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
      • Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
      • Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA
      • Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
      • Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Anesthetic Effect, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Anesthetic Effect - Pipeline by 4P Therapeutics LLC, H1 2018
  • Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H1 2018
  • Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H1 2018
  • Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2018
  • Anesthetic Effect - Pipeline by Expanesthetics Inc, H1 2018
  • Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
  • Anesthetic Effect - Pipeline by Lannett Company Inc, H1 2018
  • Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018
  • Anesthetic Effect - Pipeline by Paion AG, H1 2018
  • Anesthetic Effect - Pipeline by Phosphagenics Ltd, H1 2018
  • Anesthetic Effect - Pipeline by Physica Pharma, H1 2018
  • Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H1 2018
  • Anesthetic Effect - Pipeline by Recro Pharma Inc, H1 2018
  • Anesthetic Effect - Pipeline by The Medicines Company, H1 2018
  • Anesthetic Effect - Dormant Projects, H1 2018
  • Anesthetic Effect - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Anesthetic Effect - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Anesthetic Effect, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Targets, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top